# A ultra-stable point of care nanozyme-based kit for cTnI detection in human serum

## TL;DR

This paper introduces a highly stable, sensitive, and accurate nanozyme-based kit for detecting heart attack markers in human serum at home.

## Contribution

A novel ultra-stable nanozyme-based kit for cTnI detection with higher sensitivity and compliance than commercial alternatives.

## Key findings

- The nanozyme had peroxidase activity and effectively catalyzed TMB with an average particle size of 200 nm.
- The kit achieved a sensitivity of 1.5 ng/mL and a 92.1% compliance rate in detecting cTnI in serum.
- The kit outperformed commercial colloidal gold assay kits in detecting myocardial infarction markers.

## Abstract

Home discovery of myocardial infarction can significantly improve the rate of treatment. Cardiac troponin I (cTnI), as a biochemical marker that has been introduced into clinical diagnosis and treatment guidelines, can effectively predict the occurrence of myocardial infarction. We constructed highly stable nanozyme based on Fe3O4 nanoparticles and prepared rapid detection reagents for myocardial infarction by modifying anti-cTnI antibodies. The results showed that the nanozyme with an average particle size of 200 nm had peroxidase activity and could effectively catalyze 3,3′, 5,5′-tetramethylbenzidine (TMB). With a sensitivity of up to 1.5 ng/mL, the kit showed superior performance than commercial colloidal gold assay kits, and could effectively detect cTnI in serum with an overall compliance rate of 92.1%. The study provides a new approach to home detection of heart attacks.